about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Roche cuts two more TIG­IT tri­als, plans ac­cel­er­at­ed time­line for obe­si­ty drugs

9 months ago
R&D
Pharma

Chi­nese biotech de­vel­op­ing semaglu­tide biosim­i­lar files for Hong Kong IPO

9 months ago
Financing
China

A rare dis­ease first; Lil­ly’s Alzheimer’s push; Ar­genx’s next act; No­var­tis' obe­si­ty ap­proach; and more

9 months ago
Weekly

No­var­tis set­tles in to new nor­mal two years af­ter big re­org, even as fine-tun­ing con­tin­ues

10 months ago
Pharma

FDA thwarts Agenus' ac­cel­er­at­ed ap­proval plans for CT­LA-4/PD-1 com­bo in 'dis­ap­point­ing' move

10 months ago
R&D

Deep dive on pay pack­ages; Lil­ly strikes $3.2B buy­out; Pfiz­er’s R&D head to de­part; and more

10 months ago
Weekly

FDA re­jects No­vo Nordisk’s once-week­ly in­sulin af­ter ques­tion­ing risks

10 months ago
FDA+
Manufacturing

Ideaya show­cas­es proof-of-con­cept da­ta in a boost to syn­thet­ic lethal­i­ty play

10 months ago
R&D

Eli Lil­ly’s Alzheimer’s OK; GSK picks its mR­NA bets; Megaround tal­ly; Biose­cure's shad­ow; and more

10 months ago
Weekly

GSK re­works Cure­Vac deal, pay­ing $429M up­front to grab con­trol of mR­NA flu and Covid vac­cines 

10 months ago
Deals

As con­fi­dence falls, bio­phar­ma com­pa­nies take pre­cau­tions with Chi­nese part­ner­ships, sur­vey finds

10 months ago
China
Outsourcing

Al­ny­lam's big Phase 3 win; LGBTQ+ lead­ers chart­ing paths; Chevron over­turned; and more

10 months ago
Weekly

Sarep­ta's big gene ther­a­py ex­pan­sion; In­side Iambic's AI cy­cle; Ver­tex, Lil­ly un­veil new di­a­betes da­ta; and more

10 months ago
Weekly

BIO CEO’s pa­tri­ot­ic piv­ot; Step for­ward for Lil­ly’s Alzheimer’s drug; Pfiz­er’s gene ther­a­py set­back; ...

11 months ago
Weekly

AI drug dis­cov­ery start­up goes pub­lic in Hong Kong, nab­bing $115M to build on phar­ma part­ner­ships

11 months ago
Financing
China

Alu­mis files for IPO ahead of Phase 3 stud­ies for sec­ond-gen TYK2 in­hibitor

11 months ago
Financing

Who are the women mak­ing a mark in bio­phar­ma R&D? Nom­i­nate them for End­points’ 2024 spe­cial re­port

11 months ago
Special

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

11 months ago
Financing
China

Gen­Fleet high­lights Phase 2 da­ta on KRAS/EGFR com­bo in lung can­cer 

11 months ago
R&D
China

Mer­ck’s $3B re­turn to eye dis­ease; J&J’s $1.25B tuck-in; Keytru­da chal­lenger steals #AS­CO24 show; and more

11 months ago
Weekly

FDA de­lays Dupix­ent in COPD de­ci­sion by three months while EMA gives thumbs-up

11 months ago
FDA+

Arc­turus teas­es da­ta from small tri­al of in­hal­able cys­tic fi­bro­sis mR­NA ther­a­py, stock rock­ets 

11 months ago
R&D

Sec­ond en­gi­neered B cell ther­a­py en­ters the clin­ic, promis­ing to do in he­mo­phil­ia B what gene ther­a­pies can't

11 months ago
R&D
Cell/Gene Tx

Cal­lid­i­tas’ rare dis­ease drug draws $1B+ buy­out of­fer from Japan­ese buy­er

11 months ago
Deals
First page Previous page 12345 Next page Last page
A service from the Financial Times